Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Point success rate for patient therapeutic response prediction by continuous biomarker scores.

Ma Z, Kim Y, Hu F, Lee JK.

Stat Methods Med Res. 2016 Aug;25(4):1638-47. doi: 10.1177/0962280213493161. Epub 2013 Jul 9.

PMID:
23839122
2.
4.

Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer.

Kim Y, Guntupalli SR, Lee SJ, Behbakht K, Theodorescu D, Lee JK, Diamond JR.

PLoS One. 2014 Feb 5;9(2):e86532. doi: 10.1371/journal.pone.0086532. eCollection 2014.

5.
6.

Biomarkers as point-of-care tests to guide prescription of antibiotics in patients with acute respiratory infections in primary care.

Aabenhus R, Jensen JU, Jørgensen KJ, Hróbjartsson A, Bjerrum L.

Cochrane Database Syst Rev. 2014 Nov 6;(11):CD010130. doi: 10.1002/14651858.CD010130.pub2. Review.

PMID:
25374293
7.

Optimal chemotherapy treatment for women with recurrent ovarian cancer.

Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P.

Curr Oncol. 2007 Oct;14(5):195-208.

8.

Identifying cut points for biomarker defined subset effects in clinical trials with survival endpoints.

He P.

Contemp Clin Trials. 2014 Jul;38(2):333-7. doi: 10.1016/j.cct.2014.06.005. Epub 2014 Jun 16.

PMID:
24948401
9.

Optimal Bayesian adaptive trials when treatment efficacy depends on biomarkers.

Zhang Y, Trippa L, Parmigiani G.

Biometrics. 2016 Jun;72(2):414-21. doi: 10.1111/biom.12437. Epub 2015 Nov 17.

PMID:
26575199
10.

Improving the prediction of chemotherapeutic sensitivity of tumors in breast cancer via optimizing the selection of candidate genes.

Jiang L, Huang L, Kuang Q, Zhang J, Li M, Wen Z, He L.

Comput Biol Chem. 2014 Apr;49:71-8. doi: 10.1016/j.compbiolchem.2013.12.002. Epub 2014 Jan 1.

PMID:
24440656
11.

[The origin of informed consent].

Mallardi V.

Acta Otorhinolaryngol Ital. 2005 Oct;25(5):312-27. Italian.

PMID:
16602332
12.

Practical perspectives of personalized healthcare in oncology.

Hodgson DR, Wellings R, Harbron C.

N Biotechnol. 2012 Sep 15;29(6):656-64. doi: 10.1016/j.nbt.2012.03.001. Epub 2012 Mar 15. Review.

PMID:
22426411
13.

Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials.

Shi Q, Mandrekar SJ, Sargent DJ.

Scand J Gastroenterol. 2012 Mar;47(3):356-62. doi: 10.3109/00365521.2012.640836. Epub 2011 Dec 19. Review.

PMID:
22181041
14.

Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.

Ward S, Scope A, Rafia R, Pandor A, Harnan S, Evans P, Wyld L.

Health Technol Assess. 2013 Oct;17(44):1-302. doi: 10.3310/hta17440. Review.

15.

Value-based assessment of pharmacodiagnostic testing from early stage development to real-world use.

Burns LC, Orsini L, L'italien G.

Value Health. 2013 Sep-Oct;16(6 Suppl):S16-9. doi: 10.1016/j.jval.2013.06.007.

16.

Personalized medicine in breast cancer: a systematic review.

Cho SH, Jeon J, Kim SI.

J Breast Cancer. 2012 Sep;15(3):265-72. doi: 10.4048/jbc.2012.15.3.265. Epub 2012 Sep 28.

17.

Improving clinical trial efficiency by biomarker-guided patient selection.

Boessen R, Heerspink HJ, De Zeeuw D, Grobbee DE, Groenwold RH, Roes KC.

Trials. 2014 Apr 2;15:103. doi: 10.1186/1745-6215-15-103.

18.

Supplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Service Task Force [Internet].

Melnikow J, Fenton JJ, Whitlock EP, Miglioretti DL, Weyrich MS, Thompson JH, Shah K.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jan.

19.

The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders.

J Clin Psychiatry. 2003;64 Suppl 12:5-19.

20.

Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor.

Seidman AD, Portenoy R, Yao TJ, Lepore J, Mont EK, Kortmansky J, Onetto N, Ren L, Grechko J, Beltangady M, et al.

J Natl Cancer Inst. 1995 Sep 6;87(17):1316-22.

PMID:
7544834

Supplemental Content

Support Center